Correlation of Prognostic Biomarker SLC25A1 with Immune Infiltrates in Low-Grade Gliomas

Li Qian  
Affiliated Hospital of Nantong University

Shu-min Lu  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Xin He  
Affiliated Hospital of Nantong University

Hua Huang  
Affiliated Hospital of Nantong University

Jianguo Zhang (✉ jgz_edu@163.com)  
Affiliated Hospital of Nantong University  https://orcid.org/0000-0002-6984-8523

Research

Keywords: SLC25A1, Lower-grade glioma, Biomarker, Immune infiltrates

Posted Date: September 15th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-847314/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** Glioma is the most common primary malignant tumor of the central nervous system (CNS), and low-grade glioma (LGG) is an important pathological type of glioma. Immune infiltration of tumor microenvironment is an independent predictor of survival and prognosis in LGG patients. SLC25A1 is a gene that has not been reported in LGG. We used the TCGA database to study the expression level of SLC25A1 in LGG tissues and its relationship with the prognosis of LGG patients and tumor immune cell infiltration.

**Methods:** Download gene expression profile data and clinical information of LGG patients from the TCGA database. The expression level of SLC25A1 gene in LGG tissues and normal tissues was compared. The expression level of SLC25A1 gene in LGG tissue samples with different WHO grades and its relationship with the prognosis of patients were analyzed. The correlation between clinical information and SLC25A1 expression was analyzed by Logistic regression. The effect of SLC25A1 on survival of LGG patients was evaluated by survival module. The correlation between SLC25A1 gene expression and tumor immune cell infiltration in LGG and the effect of immune cell infiltration on the prognosis of patients were analyzed by using the relevant modules of GEPIA. The gene groups related to SLC25A1 expression were analyzed by KEGG pathway enrichment analysis. In addition, TCGA dataset was used for gene set enrichment analysis (GSEA).

**Result:** The expression level of SLC25A1 gene in LGG tissues was higher than that in normal tissues. The expression of SLC25A1 in WHO grade I LGG tissues was higher than that in WHO grade II tissues. Multivariate analysis showed that the up-regulated expression of SLC25A1 was an independent prognostic factor for good prognosis in patients with LGG. There was a correlation between the expression level of SLC25A1 and the level of immune cell infiltration of LGG, and the latter affects the prognosis of patients with LGG. In addition, GSEA also found that Neuroactive ligand receptor interaction, cell adhesion molecules cams and so on were differentially enriched in the phenotypic pathway of high expression of SLC25A1. In the Kyoto Encyclopedia of Genome and Genome (KEGG), Neuroactive ligand-receptor interaction, Morphine addiction et al have been identified as differential enrichment pathways.

**Conclusion:** SLC25A1 is the prognosis of LGG related to immune cell infiltration, and may become a biomarker of LGG grade diagnosis, immunotherapy and prognosis.

1. Introduction

Glioma is a tumor that originates from neuroectoderm cells or precursor cells, including astrocytoma, oligodendroglioma and ependymoma, which account for 75% of primary malignant tumors in the adult brain[1]. The fatality rate and disability rate are both high[2]. According to the World Health Organization (WHO) central nervous system tumor classification standard, grades I-II are low-grade gliomas (LGGs) and grades III-IV are high-grade gliomas (HGGs). LGG has a relatively good prognosis, but it may also progress to high-grade glioma with higher malignancy and aggressiveness. In recent years, advances in molecular genetics and biomarkers have brought new hope and direction for the precise diagnosis, individualized treatment and prognostic judgment of LGG [3, 4]. Finding reliable and effective biomarkers is of great significance to the basic research and clinical treatment of LGG.
The mitochondrial citrate transporter SLC25A1, also known as CIC or CTP, belongs to a family of proteins embedded in the mitochondrial membrane. It promotes the outflow of tricarboxylic acid citric acid to the cytoplasm in exchange for dicarboxylic acid cytosolic malic acid\[^5\sim7\]. Our previous work has shown that CIC is highly expressed in several tumor types, and its gene or chemical suppression has anti-tumor activity \[^8\]. But there is no report about LGG and SLC25A1.

In this study, the LGG-related sequencing data and clinical information in the American Cancer Genome Atlas (TCGA) database were used for bioinformatics analysis, the R (v.3.6.3) software and Tumor Immune Estimation Resource (GEPIA) tools were used to analyze the expression differences of SLC25A1 in different tumor tissues and normal tissues, as well as the correlation between SLC25A1 and LGG of different WHO grades and its influence on the prognosis of patients.

In order to understand tumor immune cell infiltration, this study further used the Tumor Immune Estimation Resource (TIMER) database to analyze the correlation between SLC25A1 and tumor infiltrating immune cells in LGG and the impact of tumor infiltrating cells on the prognosis of patients. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed on the gene groups related to the expression of SLC25A1 in LGG to determine the potential pathway of SLC25A1 in the occurrence, development and immune cell infiltration of LGG.

2. Results

2.1 General situation of tissue samples

A total of 529 LGG tissue samples downloaded from TCGA database were included in this study. All of them contained gene expression profile sequencing data and clinical information, including age, sex, grade, overall survival, staging, distant metastasis, survival status and other information (Table 1). Among them, there were 224 cases of WHO grade I LGG (48%) and 243 cases of WHO grade II LGG (52%). The median age of the patients was 40.5 years old (32,53).
Table 1  
LGG patient characteristics based on TCGA

| Characteristic                          | levels            | Overall |
|----------------------------------------|-------------------|---------|
| n                                      | 528               |         |
| WHO grade, n (%)                       |                   |         |
| G2                                     | 224 (48%)         |         |
| G3                                     | 243 (52%)         |         |
| IDH status, n (%)                      |                   |         |
| WT                                     | 97 (18.5%)        |         |
| Mut                                    | 428 (81.5%)       |         |
| 1p/19q codeletion, n (%)               |                   |         |
| codeletion                             | 171 (32.4%)       |         |
| non-codeletion                         | 357 (67.6%)       |         |
| Primary therapy outcome, n (%)         |                   |         |
| PD                                     | 110 (24%)         |         |
| SD                                     | 146 (31.9%)       |         |
| PR                                     | 64 (14%)          |         |
| CR                                     | 138 (30.1%)       |         |
| Gender, n (%)                          |                   |         |
| Female                                 | 239 (45.3%)       |         |
| Male                                   | 289 (54.7%)       |         |
| Race, n (%)                            |                   |         |
| Asian                                  | 8 (1.5%)          |         |
| Black or African American              | 22 (4.3%)         |         |
| White                                  | 487 (94.2%)       |         |
| Age, n (%)                             |                   |         |
| <=40                                   | 264 (50%)         |         |
| > 40                                   | 264 (50%)         |         |
| Histological type, n (%)               |                   |         |
| Astrocytoma                            | 195 (36.9%)       |         |
| Oligoastrocytoma                       | 134 (25.4%)       |         |
| Oligodendroglioma                      | 199 (37.7%)       |         |
| Laterality, n (%)                      |                   |         |
| Left                                   | 256 (48.9%)       |         |
| Midline                                | 6 (1.1%)          |         |
| Right                                  | 261 (49.9%)       |         |
| OS event, n (%)                        |                   |         |
| Alive                                  | 392 (74.2%)       |         |
| Dead                                   | 136 (25.8%)       |         |
| DSS event, n (%)                       |                   |         |
| Alive                                  | 397 (76.3%)       |         |

PD (progressive disease), SD (stable disease), PR (partial response), CR (complete response)
| Characteristic | levels | Overall |
|----------------|--------|---------|
|                | Dead   | 123 (23.7%) |
| PFI event, n (%) | Alive | 318 (60.2%) |
|                | Dead   | 210 (39.8%) |
| Age, median (IQR) |       | 40.5 (32, 53) |

2.2 Expression level of SLC25A1 gene in tumor and normal tissues

The results of Oncomine database analysis showed that SLC25A1 gene was highly expressed in brain and central nervous system tumor data sets (P < 0.001, multiple of difference > 1.5). SLC25A1 was highly expressed in Bladder Urothelial carcinoma, Colon adenocarcinoma, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma, Esophageal carcinoma, Glioblastoma multiforme, Head and Neck squamous cell carcinoma and other data sets (P < 0.001, Fig. 1).

In order to further evaluate the expression of SLC25A1 gene in LGG tissues, we analyzed the transcriptional level of SLC25A1 based on TCGA database. We found that the expression of SLC25A1 gene in LGG tissues was higher than that in normal tissues (p < 0.001, Fig. 2). In addition, SLC25A1 mRNA was also expressed differently in different age, sex, WHO grade, primary therapy outcome, IDH and 1p19q status groups. The results showed that the expression level of SLC25A1 in IDH Mut group was higher than that in WT group (P < 0.001), and the expression level of SLC25A1 in 1p19q non-codeletion group was lower than that in codeletion group (P = 0.031). In the primary therapy outcome group, SLC25A1 expression was higher in the PR group than in the PD group (P < 0.001), and higher in the CR group than in the PD group (P = 0.002). The average level in PR group was higher than that in SD group (P = 0.028). The expression of SLC25A1 in Male group was higher than that in Female group (P = 0.024). Most patients with high SLC25A1 expression were less than or equal to 40 years old (P = 0.003). The expression level of SLC25A1 gene in WHO grade II LGG tissue was higher than that in WHO grade I LGG tissues, and the median difference between the two groups was 0.152 (-0.265 - -0.036), with statistical significance (P = 0.01, Fig. 3).

2.3 Correlation between clinical characteristics and SLC25A1 gene expression in patients with LGG

In this study, chi-square test was used to analyze the correlation between clinical characteristics and SLC25A1mRNA expression in patients with LGG (Table 2). According to the expression level of SLC25A1 mRNA, they were divided into high expression group and low expression group. The results showed that the high expression of SLC25A1 mRNA was related to IDH status (P < 0.001), Primary therapy outcome (< 0.001), Age (P = 0.019), Histological type (P = 0.015) and survival status (P < 0.001), respectively.
Table 2
Relationship between SLC25A1 mRNA expression and clinical characteristics in LGG.

| Characteristic                             | levels         | Low expression of SLC25A1 | High expression of SLC25A1 | p       |
|-------------------------------------------|----------------|---------------------------|----------------------------|---------|
| n                                         | 264            | 264                       |                            |         |
| WHO grade, n (%)                          | G2             | 111 (23.8%)               | 113 (24.2%)                | 0.196   |
|                                           | G3             | 136 (29.1%)               | 107 (22.9%)                |         |
| IDH status, n (%)                         | WT             | 82 (15.6%)                | 15 (2.9%)                  | < 0.001 |
|                                           | Mut            | 179 (34.1%)               | 249 (47.4%)                |         |
| 1p/19q codeletion, n (%)                  | codeletion     | 75 (14.2%)                | 96 (18.2%)                 | 0.063   |
|                                           | non-codeletion | 189 (35.8%)               | 168 (31.8%)                |         |
| Primary therapy outcome, n (%)            |                |                            |                            | < 0.001 |
| PD                                        | 74 (16.2%)     | 36 (7.9%)                 |                            |         |
| SD                                        | 79 (17.2%)     | 67 (14.6%)                |                            |         |
| PR                                        | 20 (4.4%)      | 44 (9.6%)                 |                            |         |
| CR                                        | 57 (12.4%)     | 81 (17.7%)                |                            |         |
| Gender, n (%)                             |                |                            |                            |         |
| Female                                    | 131 (24.8%)    | 108 (20.5%)               |                            | 0.054   |
| Male                                      | 133 (25.2%)    | 156 (29.5%)               |                            |         |
| Race, n (%)                               |                |                            |                            |         |
| Asian                                     | 3 (0.6%)       | 5 (1%)                    |                            | 0.070   |
| Black or African American                 | 16 (3.1%)      | 6 (1.2%)                  |                            |         |
| White                                     | 240 (46.4%)    | 247 (47.8%)               |                            |         |
| Age, n (%)                                |                |                            |                            |         |
| <=40                                      | 118 (22.3%)    | 146 (27.7%)               |                            | 0.019   |
| > 40                                      | 146 (27.7%)    | 118 (22.3%)               |                            |         |
| Histological type, n (%)                  |                |                            |                            |         |
| Astrocytoma                               | 108 (20.5%)    | 87 (16.5%)                |                            | 0.015   |
| Oligoastrocytoma                          | 53 (10%)       | 81 (15.3%)                |                            |         |
| Oligodendroglioma                         | 103 (19.5%)    | 96 (18.2%)                |                            |         |
| Laterality, n (%)                         |                |                            |                            |         |
| Left                                      | 118 (22.6%)    | 138 (26.4%)               |                            | 0.075   |
| Midline                                   | 5 (1%)         | 1 (0.2%)                  |                            |         |
| Right                                     | 139 (26.6%)    | 122 (23.3%)               |                            |         |

PD (progressive disease), SD (stable disease), PR (partial response), CR (complete response)
| Characteristic       | levels | Low expression of SLC25A1 | High expression of SLC25A1 | p      |
|---------------------|--------|---------------------------|---------------------------|--------|
| OS event, n (%)     | Alive  | 176 (33.3%)               | 216 (40.9%)               | < 0.001|
|                     | Dead   | 88 (16.7%)                | 48 (9.1%)                 |        |
| DSS event, n (%)    | Alive  | 178 (34.2%)               | 219 (42.1%)               | < 0.001|
|                     | Dead   | 82 (15.8%)                | 41 (7.9%)                 |        |
| PFI event, n (%)    | Alive  | 136 (25.8%)               | 182 (34.5%)               | < 0.001|
|                     | Dead   | 128 (24.2%)               | 82 (15.5%)                |        |
| Age, median (IQR)   |        | 42.5 (33, 57)             | 38 (31, 49)               | 0.002  |

PD (progressive disease), SD (stable disease), PR (partial response), CR (complete response)

### 2.4 Diagnostic value of SLC25A1 mRNA expression in LGG

In this study, the diagnostic value of SLC25A1 mRNA expression in LGG was evaluated by ROC curve. The results showed that the area under the curve of SLC25A1 was 0.964, which had good diagnostic value (Fig. 4). Since then, we have constructed a nomogram to predict the 1-, 3- and 5-year survival probability of patients by combining the expression level of SLC25A1 and clinical variables (Fig. 5).

### 2.5 The high expression of SLC25A1 mRNA is an independent risk factor affecting the overall survival of patients with LGG

The expression of SLC25A1 gene in LGG tissue samples with different WHO grades was calculated according to UALCAN. The results of survival analysis showed that the survival prognosis of the group with high expression of SLC25A1 gene (n = 264) was better than that of the group with low expression (n = 263), overall survival (OS) (HR = 0.54, 95% CI = 0.38–0.77, P = 0.001 Fig. 6A), Disease Specific Survival (DSS) (HR = 0.49, 95% CI = 0.34–0.72, P < 0.001 Fig. 6B), progression-free interval (PFI) (HR = 0.55, 95% CI = 0.42–0.73, P < 0.001 Fig. 6C).

As shown in the Table 3, univariate Cox regression analysis showed that SLC25A1 expression level, WHO grade (P < 0.001), 1p/19q codeletion (P < 0.001), primary therapy outcome (P < 0.001), ERBB2 expression (P < 0.004), TP53 (P < 0.012), IDH status (P < 0.001), Age (P < 0.001) and histological type (P < 0.001) were related to the overall prognosis of the patients.
### Table 3
Association between clinicopathologic characteristics and LGG patient OS through univariate analysis with Cox regression survival model.

| Characteristics                                      | Total(N) | Univariate analysis | Hazard ratio (95% CI) | P value |
|-------------------------------------------------------|----------|---------------------|-----------------------|---------|
| WHO grade (G3 vs. G2)                                 | 466      |                     | 3.059 (2.046–4.573)   | < 0.001 |
| 1p/19q codeletion (non- codeletion vs. codeletion)    | 527      |                     | 2.493 (1.590–3.910)   | < 0.001 |
| Primary therapy outcome (PR&CR vs. PD&SD)            | 457      |                     | 0.202 (0.113–0.359)   | < 0.001 |
| ERBB2 (High vs. Low)                                 | 527      |                     | 1.676 (1.185–2.370)   | 0.004   |
| TP53 (High vs. Low)                                  | 527      |                     | 1.558 (1.104–2.197)   | 0.012   |
| IDH status (Mut vs. WT)                               | 524      |                     | 0.186 (0.130–0.265)   | < 0.001 |
| Gender (Male vs. Female)                              | 527      |                     | 1.124 (0.800–1.580)   | 0.499   |
| Age (> 40 vs. <=40)                                   | 527      |                     | 2.889 (2.009–4.155)   | < 0.001 |
| Laterality (Midline &Right vs. Left)                  | 522      |                     | 0.776 (0.548–1.099)   | 0.154   |
| SLC25A1 (High vs. Low)                                | 527      |                     | 0.540 (0.379–0.768)   | < 0.001 |
| Race (Black or African American &White vs. Asian)     | 516      |                     | 3334251.560 (0.000-Inf) | 0.993 |
| Histological type (Oligoastrocytoma &Oligodendroglioma vs. Astrocytoma) | 527 | | 0.606 (0.430–0.853) | 0.004 |

Multivariate Cox regression analysis showed that WHO grade (P = 0.005), 1p/19q codeletion (P = 0.008), primary therapy outcome (P < 0.001), IDH status (P = 0.001), Age (P < 0.001) and SLC25A1 expression level (P = 0.042) were independent prognostic factors in LGG patients (Fig. 7).

### 2.6 Relationship between tumor immune cell infiltration and SLC25A1 gene expression and its effect on prognosis of patients
Previous analysis showed that tumor infiltrating lymphocytes were independent predictors of sentinel lymph node status and survival in cancer patients[9]. Therefore, we try to find out whether the expression of SLC25A1 is related to the immune infiltration of LGG. Spearman partial correlation analysis showed that the expression level of SLC25A1 gene was related to 24 kinds of immune cells (Fig. 8). Among them, SLC25A1 was positively correlated with the infiltration level of tumor immune CD8+ T cells ($r_s = 0.220, P < 0.001$), and negatively correlated with Tcm ($r_s = -0.170, P < 0.001$), Thelper ($r_s = -0.140, P = 0.001$), TFH ($r_s = -0.220, P < 0.001$), Th1 ($r_s = -0.280, P < 0.001$), Th2 ($r_s = -0.270, P < 0.001$), aDC ($r_s = -0.110, P = 0.012$), B cells ($r_s = -0.290, P < 0.001$), Cytotoxic ($r_s = -0.160, P < 0.001$), Eosinophils ($r_s = -0.320, P < 0.001$), iDC ($r_s = -0.097, P = 0.025$), Macrophages ($r_s = -0.220, P < 0.001$), Mast ($r_s = -0.340, P < 0.001$), Neutrophils ($r_s = -0.180, P < 0.001$), CD56bright cells ($r_s = -0.140, P = 0.001$), CD56dim cells ($r_s = -0.093, P = 0.033$), NK cells ($r_s = -0.130, P = 0.002$), T cells ($r_s = -0.280, P < 0.001$) (Fig. 9).

Through the analysis of the relationship between the infiltration level of different immune cells and the survival and prognosis of patients with LGG, it was found that the infiltration level of B cells, Macrophage, Neutrophil would affect the overall prognosis of patients with LGG (Fig. 10).

### 2.7 Results of KEGG pathway enrichment analysis of gene groups positively related to SLC25A1 gene expression

As the high expression of SLC25A1 gene is a risk factor for the survival and prognosis of patients with LGG, we used UALCAN correlation analysis to obtain a total of 56494 genes related to SLC25A1 gene expression in LGG tissues, and used DAVID database for KEGG pathway enrichment analysis. The results showed that under the condition of p.adj < 0.05 and q value < 0.2, there were 1 BP, 13 CC, 37 MF and 1 KEGG (Table 4 and Fig. 11).
Table 4  
The Functions of SLC25A1 and Genes Significantly Associated with SLC25A1 Alterations.

| ONTOLOGY | ID       | Description                                           | GeneRatio | BgRatio   | pvalue    | p.adjust  | qvalue    |
|----------|----------|-------------------------------------------------------|-----------|-----------|-----------|-----------|-----------|
| BP       | GO:0007218 | neuropeptide signaling pathway                         | 7/67      | 104/18670 | 8.97e-08  | 8.63e-05  | 7.67e-05  |
| BP       | GO:2001257 | regulation of cation channel activity                 | 5/67      | 178/18670 | 4.46e-04  | 0.090     | 0.080     |
| BP       | GO:0048562 | embryonic organ morphogenesis                          | 6/67      | 288/18670 | 5.80e-04  | 0.090     | 0.080     |
| BP       | GO:0021761 | limbic system development                              | 4/67      | 109/18670 | 6.35e-04  | 0.090     | 0.080     |
| BP       | GO:0034776 | response to histamine                                 | 2/67      | 11/18670  | 6.83e-04  | 0.090     | 0.080     |
| CC       | GO:0034702 | ion channel complex                                    | 9/73      | 301/19717 | 1.65e-06  | 1.51e-04  | 1.23e-04  |
| CC       | GO:1902495 | transmembrane transporter complex                      | 9/73      | 324/19717 | 3.01e-06  | 1.51e-04  | 1.23e-04  |
| CC       | GO:1990351 | transporter complex                                    | 9/73      | 332/19717 | 3.68e-06  | 1.51e-04  | 1.23e-04  |
| CC       | GO:0034703 | cation channel complex                                 | 7/73      | 220/19717 | 1.71e-05  | 5.25e-04  | 4.27e-04  |
| CC       | GO:0008076 | voltage-gated potassium channel complex               | 4/73      | 87/19717  | 3.05e-04  | 0.008     | 0.006     |
| MF       | GO:0022839 | ion gated channel activity                             | 10/68     | 334/17697 | 5.52e-07  | 5.42e-05  | 3.63e-05  |
| MF       | GO:0022836 | gated channel activity                                 | 10/68     | 343/17697 | 7.04e-07  | 5.42e-05  | 3.63e-05  |
| MF       | GO:0005216 | ion channel activity                                   | 10/68     | 416/17697 | 3.98e-06  | 1.97e-04  | 1.32e-04  |
| MF       | GO:0022838 | substrate-specific channel activity                    | 10/68     | 428/17697 | 5.12e-06  | 1.97e-04  | 1.32e-04  |
| MF       | GO:0015267 | channel activity                                       | 10/68     | 456/17697 | 8.93e-06  | 2.33e-04  | 1.56e-04  |
| KEGG     | hsa04080  | Neuroactive ligand-receptor interaction                | 8/25      | 341/8076  | 5.36e-06  | 2.95e-04  | 2.59e-04  |
2.8 GSEA identifies signaling pathways associated with SLC25A1

GSEA is used to identify signaling pathways that are activated in LGG. The results showed that Neuroactive ligand receptor interaction, cell adhesion molecules cam, core matrisome, CD8+ T cell downstream pathway, acetylcholine neurotransmitter release cycle, barrestin pathway were differentially enriched in the negatively correlated with SLC25A1 mRNA expression phenotype (Fig. 12).

3. Discussion

Glioma is the most common primary malignant tumor of the central nervous system (CNS). It originates from glial cells in the brain and has a high degree of malignancy. The World Health Organization (WHO) (2016) classifies gliomas into grades I-IV, of which grade I and  are low-grade gliomas (LGG) [10], accounting for 40%-50% of CNS tumors under 18 years of age. LGG is characterized by slow growth and even growth stagnation [11]. Most of the patients with LGG are treated with comprehensive therapy, including surgery, radiotherapy and chemotherapy. However, the existing treatment methods can only improve the clinical symptoms of patients, cannot be cured, often occur drug resistance and tumor recurrence [12], and more than half of LGG can develop into high-level LGG that is difficult to treat [13].

In recent years, some new treatments, such as immunotherapy, have been adopted, but the prognosis of patients is still not ideal, which may be related to the lack of effective diagnosis and treatment targets. The SLC25A1 we studied in this article may provide a potential molecular target for the diagnosis, treatment and prognosis of LGG. The discovery of the relationship between SLC25A1 and tumor immune cell infiltration may contribute to the development of LGG immunotherapy.

The mitochondrial citrate transporter, SLC25A1 belongs to the family of ion transporters embedded in the mitochondrial membrane, and its defects have been indirectly related to a variety of human diseases[5, 6, 14]. The human SLC25A1 gene is located on the chromosome 22q11.21 [15, 16]. The expression of SLC25A1 is induced by insulin and inflammation, and its activity is lost in type  diabetes. SLC25A1 can also be expressed in a variety of cancer tissues, including ovarian cancer, colon cancer and so on[17]. Previous studies have also shown an increase in SLC25A1 activity in liver tumors [18–21]. In addition, mutations in members of the tricarboxylate transporter family in fruit fly, INDY, which can prolong the lifespan, thus indicating that the citrate transporter pathway also controls longevity[22].

The potential prognostic effects of SLC25A1 in LGG have not been reported. Compared with normal cells, most tumor cells show metabolic changes, which is closely related to the development, progression and invasiveness of cancer[23]. These metabolic changes are largely due to the different utilization of citric acid from normal cells. In fact, it has been suggested that in cancer cells, citric acid is mainly exported from the mitochondria through CIC, and then cleaved in the cytoplasm by citrate lyase (CLY) to support lipid, acetyl-CoA
and macromolecular biosynthesis[24–26]. This shift in citric acid metabolism from mitochondria to cytoplasm is thought to explain the acquisition of lipogenic phenotypes, as well as the high percentage of anaerobic glycolysis (Warburg effect), which represents the characteristics of many cancer cells[27]. Therefore, we studied the potential role of SLC25A1 in LGG and analyzed the expression of SLC25A1 in a large number of human glioma tumor specimens for the first time. Under the background of clinical and RNA sequence data, 529 patients with LGG were retrospectively analyzed and histologically confirmed. Through the study, we observed that the expression of SLC25A1 in normal LGG tissues was different from that in tumor tissues, and the expression of SLC25A1 in LGG tissues was higher than that in normal tissues. In addition, the expression level of SLC25A1mRNA was related to tumor grade. The expression level in LGG tissues of WHO I was higher than that in LGG tissues of WHO II. The results of survival analysis showed that the expression level of SLC25A1 gene was related to the prognosis of LGG, and the prognosis of patients with high expression might be better. Multivariate Cox regression analysis showed that the level of SLC25A1 gene expression was an independent risk factor for the prognosis of patients with LGG. At the same time, the results of ROC curve suggest that SLC25A1 has a good diagnostic value.

The prognosis of LGG is affected by age, location, degree of nerve injury, resection extent, gene phenotype and so on. The prognosis and progression of LGG in children and adults are different, and adult LGG is more likely to develop into malignant LGG [28]. Because of the heterogeneity of LGG, the tumor usually shows different molecular characteristics, so the prognosis is different [28]. In recent years, the research on prognostic biomarkers of LGG has been gradually deepened and enriched. According to the status of IDH mutation and 1p/19q deletion, WHO (2016) can be divided into three categories: IDH wild type, IDH mutation and 1p/19q intact, IDH mutation and 1p/19q co-deletion. Among them, the prognosis of IDH wild type is the worst[29], while the expression of IDH mutation in LGG patients indicates a good prognosis [30]. In an article published by Professor Jiang et al. [31], 77% of WHO II gliomas had IDH1 mutations, with a mutation rate of 55% in WHO II and only 6% in WHO IV. And Professor Yan et al. [32] believe that IDH1 mutation is positively related to the prognosis of tumor treatment. Previous experiments have once again confirmed the significance of IDH1 mutation, that is, detection of IDH1 mutation can be used as an independent index to evaluate the prognosis of glioma patients. IDH1 mutation is more common in low-grade glioma patients, and the progression-free survival time of this type of patients is also relatively long[33]. An article published by Professor Brat et al. [34] pointed out that loss of heterozygosity of 1p/19q is common in oligodendrogliomas, and it is often accompanied by IDH mutation. The view of this study is that the molecular pathological typing based on IDH1 gene mutation combined with 1p/19q co-deletion can more accurately judge the recovery and survival of patients than traditional histopathological typing. The results of this study showed that the expression level of SLC25A1 in IDH mutation group and chromosome 1p19q co-deletion group was significantly higher than that in wild type group (P<0.001) and non-deletion group (P<0.001). The progress in the study of molecular markers will also promote the development of new technologies for brain tumors and further reduce the pain of patients while accurate diagnosis and treatment. The immunotherapy of LGG needs to be further studied.

Some studies have shown that tumor infiltrating immune cells are independent predictors of sentinel lymph node status and prognosis of tumor patients [9]. The genomic variation of tumor cells may produce tumor antigens, which are systematically recognized as non-self-components, thus triggering cellular immune response[35]. In recent years, it is considered that T cells are related to the positive prognosis of patients [36]. The role of B cells in solid tumors show that the expression of CD20 is related to the prolongation of overall
survival in patients with breast and ovarian cancer [37]. Another previous study showed that there was a high correlation between T and B cell gene expression in all tumor types that had been evaluated [38, 39]. The results of a previous study showed that there was a high correlation between T cell and B cell gene expression in all assessed tumor types. The expression of immune signals has a strong correlation between different types of immune cells, showing a diversified, but quite predictable and consistent tumor immune infiltration, and B cells support anti-tumor immune response[40, 41].

LGG has significant heterogeneity in genetics and immune level, and finding a suitable target is still a key factor affecting LGG immunotherapy [42]. In this study, we analyzed the correlation between SLC25A1 gene expression and LGG immune cell infiltration and the effect of immune cell infiltration on the prognosis of patients. Our results showed that different immune markers and immune infiltration levels were related to the expression of SLC25A1 in LGG. Among them, SLC25A1 was positively correlated with tumor immune T cells and pDC infiltration, and negatively correlated with Tcm, Thelper, TFH, Th1, Th2, aDC, B cells, Cytotoxic, Eosinophils, iDC, Macrophages, Mast, Neutrophils, CD56bright cells, CD56dim cells, NK cells, T cells. In addition, the infiltration levels of B cells, Macrophage and Neutrophil all affect the overall prognosis of LGG patients. Therefore, we think that SLC25A1 may have a potential effect on tumor immunity. In addition, it can also be used as a promising biomarker of cancer.

In this study, KEGG pathway enrichment analysis was carried out on the genes with significant correlation with SLC25A1 gene expression in LGG tissues, in order to obtain the pathways that mainly produce biological functions. The results showed that there were gene enrichment in Neuroactive ligand-receptor interaction, Morphine addiction and neuropeptide signaling pathway pathways, which suggested that most of the genes positively related to SLC25A1 gene expression might regulate the immune cell infiltration of LGG and affect the prognosis of patients through these pathways.

Finally, based on GSEA, we further studied the function of SLC25A1 and the possible mechanism of SLC25A1 affecting the progress and metastasis of LGG. GSEA has wide applicability and is one of the most used methods in path enrichment analysis. Compared with traditional pathway enrichment analysis such as Gene Ontology (GO) and Kyoto Encyclopedia of Gene and Genome (KEGG), GSEA can detect changes in the expression of gene sets rather than individual genes, and can detect subtle enrichment signals, which makes the results more reliable and flexible [43]. With the development of GSEA, we found that Neuroactive ligand receptor interaction, cell adhesion molecules cams, core matrisome, CD8 tcr downstream pathway, acetylcholine neurotransmitter release cycle, barrestin pathway were differentially enriched in the negatively correlated with SLC25A1 mRNA expression phenotype.

Although our current study improves our understanding of the role of SLC25A1 in LGG, some limitations remain. First, the sample size of cancer patients in the TCGA database was significantly higher than that of the control group. Second, the lack of specific details of patient medication and/or surgical treatment in public databases can also affect the evaluation of patient outcomes. Third, the protein level of SLC25A1 in KGG and its direct role in LGG progression and metastasis need to be further verified in vitro. Fourth, due to the limitations of GSEA, there are still few studies on SLC25A1, which may miss other important signaling pathways regulated by SLC25A1. Finally, this study is a retrospective study, and prospective studies should be conducted in the future to make up for the limitations of retrospective studies. Although this study has certain
limitations, it does provide clues for studying the function of SLC25A1 in LGG, and provides targets and potential prognostic markers for the treatment of LGG.

4. Conclusion

SLC25A1 expression is a potential molecular marker for evaluating the prognosis of LGG patients. Signal pathways such as Neuroactive ligand-receptor interaction, neuropeptide signaling pathway regulated by SLC25A1 in LGG tissues may affect tumor immune cell infiltration, which in turn affects tumor occurrence, development and patient prognosis. As an independent prognostic factor of LGG patients, SLC25A1 has the potential to become a molecular target for the treatment of LGG.

5. Materials And Methods

5.1. Data collection and preprocessing

From the TCGA database (https://portal.gdc.cancer.gov), we screened and downloaded the clinical information and tissue gene expression profile data of 529 LGG patients, all of which were tumor tissues and no normal tissues. Due to the lack of normal tissue control, the gene expression profile data of 5 normal brain tissues of patients with glioblastoma multiforme were screened and downloaded from the TCGA database for control analysis. Check the integrity of the downloaded data and delete cases that completely lack clinical information or lack key data such as survival status or survival time. Convert the gene code to the standard gene name of the American Gene Nomenclature Committee (HUGO Gene Nomenclature Committee, HGNC). The gene expression and clinical characteristics of TCGA. The relevant data provided by TCGA is public and open, and does not require the approval of the local ethics committee.

5.2 Analysis of the expression level of SLC25A1 gene in tumor tissues and normal tissues

The Oncomine database (https://www.oncomine.org/resource/login.html) was used to identify the expression level of SLC25A1 gene in various types of tumor tissues. Screening conditions: P < 0.05, multiple of difference > 1.5, the top 10% of genes are ranked, and the data type is mRNA. To compare and analyze the expression level of SLC25A1 gene in some tumor tissues and normal tissues in the TCGA database.

5.3 Expression analysis of SLC25A1 gene in LGG tissues of different WHO grades and its relationship with patient prognosis

Use the cancer data online analysis and mining website UALCAN (http://ualcan.path.uab.edu/index.html) to analyze the LGG data in the TCGA database. Calculate the expression of SLC25A1 gene in LGG tissue samples of different WHO grades. GEPIA (http://gepia.cancer-pku.cn/index.html) was used to compare the expression of SLC25A1 gene in normal brain tissues and LGG tissues. According to the median of SLC25A1 gene expression, the cases were divided into high expression group and low expression group, and survival curves were drawn.
5.4 Analysis of clinical characteristics and SLC25A1 gene expression on prognosis of LGG patients

The classification of case data was converted to assign values, and the clinical characteristics and SLC25A1 gene expression level of LGG patients were analyzed by univariate and multivariate Cox regression analysis with R (v.3.6.3) software to analyze the impact on the prognosis of patients.

5.5 Analysis of the relationship between tumor immune cell infiltration and SLC25A1 gene expression and its effect on the prognosis of patients

The markers of 24 immune cells were extracted from the study of Bindea and his colleagues[44]. The infiltration of 24 kinds of immune cells in tumor was analyzed by GSEA method, and the correlation between SLC25A1 and these 24 kinds of immune cells was analyzed by Spearman correlation. The absolute values of binding strength of immune infiltrating cells to SLC25A1 were as follows: 0.00–0.05, very weak; 0.06–0.10, weak; 0.11–0.15, moderate; >0.15, strong. In statistical analysis, p < 0.05 was considered to be statistically significant.

5.6 Enrichment analysis of GESA

GSEA is a method that can be used for analysis and calculation to determine whether a priori defined set of genes has consistent and statistically significant differences between the two biological states[43]. In this study, we used R (v.3.6.3) to analyze the correlation between SLC25A1mRNA expression and all genes, and then used the cluster Profiler software package in R (v.3.6.3) for GSEA analysis. |ES| > 1 (P < 0.05) and FDR < 0.25 are significantly enriched[43, 45].

5.7 Enrichment Analysis of KEGG Pathway of genes positively correlated with SLC25A1 Gene expression

The gene groups which were positively correlated with SLC25A1 gene expression in LGG tissues were obtained by correlation analysis by UALCAN. The KEGG pathway enrichment analysis was carried out by using DAVID database (https://david.Ncifcrf.gov/home.jsp). The pathways with the top 10 enrichment ratios and P < 0.01 were selected, and the bubble chart was drawn by R (v.3.6.3) software.

5.8 Statistical analysis by R (v.3.6.3)

SPSS26.0 and R (v.3.6.3) software were used for analysis. Measurement data are expressed as median (lower quartile, upper quartile), using nonparametric Mann-Whitney U test; counting data are expressed as examples and percentages. The survival curve was drawn by Kaplan-Meier method, and the survival rate was compared by log-rank test. Univariate and multivariate Cox regression were used to analyze the clinical characteristics and the effect of SLC25A1 gene expression on the prognosis of LGG patients. Spearman partial correlation analysis was used to analyze the relationship between SLC25A1 gene expression and tumor immune infiltrating cells. The test level (α) was 0.05.
Declarations

Ethics approval and consent to participate
Not applicable

Consent for publication
All authors agreed to submit the manuscript to BioMedical Engineering OnLine

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Competing interests
The authors declare that they have no competing interests.

Funding
This study was funded by the Scientific Research Project of Nantong Municipal Health Commission (No. QA2019060).

Authors' contributions
Qian Li and Lu Shu-min conceived the project and wrote the manuscript. Qian Li and He Xin participated in data analysis. Huang Hua and Zhang Jian-guo participated in discussion. Zhang Jianguo-guo reviewed the manuscript.

Acknowledgements
Not applicable.

References
1. Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet (London, England). 2018,392(10145):432-46. Epub 2018/08/01. doi: 10.1016/s0140-6736(18)30990-5. PubMed PMID: 30060998.

2. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021. Epub 2021/06/30. doi: 10.1093/neuonc/noab106. PubMed PMID: 34185076.

3. de Blank P, Fouladi M, Huse JT. Molecular markers and targeted therapy in pediatric low-grade glioma. J Neurooncol. 2020,150(1):5-15. Epub 2020/05/14. doi: 10.1007/s11060-020-03529-1. PubMed PMID: 32399739.

4. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nature reviews Clinical oncology. 2017,14(7):434-52.
5. Palmieri F, Pierri CL. Mitochondrial metabolite transport. Essays Biochem. 2010;47:37-52. Epub 2010/06/11. doi: 10.1042/bse0470037. PubMed PMID: 20533899.

6. Palmieri F. Diseases caused by defects of mitochondrial carriers: a review. Biochimica et biophysica acta. 2008;1777(7-8):564-78. Epub 2008/04/15. doi: 10.1016/j.bbabio.2008.03.008. PubMed PMID: 18406340.

7. Sun J, Aluvila S, Kotaria R, Mayor JA, Walters DE, Kaplan RS. Mitochondrial and Plasma Membrane Citrate Transporters: Discovery of Selective Inhibitors and Application to Structure/Function Analysis. Molecular and cellular pharmacology. 2010;2(3):101-10. Epub 2010/08/06. PubMed PMID: 20686672, PubMed Central PMCID: PMC2913483.

8. Catalina-Rodriguez O, Kolukula VK, Tomita Y, Preet A, Palmieri F, Wellstein A, et al. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget. 2012;3(10):1220-35. Epub 2012/10/27. doi: 10.18632/oncotarget.714. PubMed PMID: 23100451, PubMed Central PMCID: PMC3717962.

9. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(21):2678-83. Epub 2012/06/20. doi: 10.1200/jco.2011.37.8539. PubMed PMID: 22711850.

10. Perry A, Wesseling P. Histologic classification of gliomas. Handb Clin Neurol. 2016;134:71-95. Epub 2016/03/08. doi: 10.1016/b978-0-12-802997-8.00005-0. PubMed PMID: 26948349.

11. Gnekow AK, Kandels D, Tilburg CV, Azizi AA, Opocher E, Stokland T, et al. SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma. Klin Padiatr. 2019;231(3):107-35. Epub 2019/05/21. doi: 10.1055/a-0889-8256. PubMed PMID: 31108561.

12. Tan Y, Zhang S, Xiao Q, Wang J, Zhao K, Liu W, et al. Prognostic significance of ARL9 and its methylation in low-grade glioma. Genomics. 2020;112(6):4808-16. Epub 2020/09/04. doi: 10.1016/j.ygeno.2020.08.035. PubMed PMID: 32882327, PubMed Central PMCID: PMC7462573.

13. Zhang M, Wang X, Chen X, Zhang Q, Hong J. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. Front Genet. 2020;11:363. Epub 2020/05/01. doi: 10.3389/fgene.2020.00363. PubMed PMID: 32351547, PubMed Central PMCID: PMC7174786.

14. Nicholls DG. Mitochondrial ion circuits. Essays Biochem. 2010;47:25-35. Epub 2010/06/11. doi: 10.1042/bse0470025. PubMed PMID: 20533898.

15. Meechan DW, Maynard TM, Tucker ES, LaMantia AS. Three phases of DiGeorge/22q11 deletion syndrome pathogenesis during brain development: patterning, proliferation, and mitochondrial functions of 22q11 genes. Int J Dev Neurosci. 2011;29(3):283-94. Epub 2010/09/14. doi: 10.1016/j.ijdevneu.2010.08.005. PubMed PMID: 20833244, PubMed Central PMCID: PMC3770287.

16. Stoffel M, Karayiorgou M, Espinosa R, 3rd, Beau MM. The human mitochondrial citrate transporter gene (SLC20A3) maps to chromosome band 22q11 within a region implicated in DiGeorge syndrome, velocardio-facial syndrome and schizophrenia. Hum Genet. 1996;98(1):113-5. Epub 1996/07/01. doi: 10.1007/s004390050169. PubMed PMID: 8682495.

17. Cheng L, Lu W, Kulkarni B, Pejovic T, Yan X, Chiang JH, et al. Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies. Gynecologic oncology.
18. Infantino V, Convertini P, Cucci L, Panaro MA, Di Noia MA, Calvello R, et al. The mitochondrial citrate carrier: a new player in inflammation. Biochem J. 2011,438(3):433-6. Epub 2011/07/27. doi: 10.1042/bj20111275. PubMed PMID: 21787310.

19. Infantino V, Iacobazzi V, De Santis F, Mastrapasqua M, Palmieri F. Transcription of the mitochondrial citrate carrier gene: role of SREBP-1, upregulation by insulin and downregulation by PUFA. Biochemical and biophysical research communications. 2007,356(1):249-54. Epub 2007/03/14. doi: 10.1016/j.bbrc.2007.02.114. PubMed PMID: 17350599.

20. Kaplan RS, Mayor JA, Blackwell R, Wilson GL, Schaffer SW. Functional levels of mitochondrial anion transport proteins in non-insulin-dependent diabetes mellitus. Molecular and cellular biochemistry. 1991,107(1):79-86. Epub 1991/09/18. doi: 10.1007/bf02424578. PubMed PMID: 1838403.

21. Kaplan RS, Morris HP, Coleman PS. Kinetic characteristics of citrate influx and efflux with mitochondria from Morris hepatomas 3924A and 16. Cancer research. 1982,42(11):4399-407. Epub 1982/11/01. PubMed PMID: 7127281.

22. Rogina B, Reenan RA, Nilsen SP, Helfand SL. Extended life-span conferred by cotransporter gene mutations in Drosophila. Science. 2000,290(5499):2137-40. Epub 2000/12/16. doi: 10.1126/science.290.5499.2137. PubMed PMID: 11118146.

23. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Power surge: supporting cells "fuel" cancer cell mitochondria. Cell Metab. 2012,15(1):4-5. Epub 2012/01/10. doi: 10.1016/j.cmet.2011.12.011. PubMed PMID: 2225869.

24. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011,481(7381):380-4. Epub 2011/11/22. doi: 10.1038/nature10602. PubMed PMID: 22101433, PubMed Central PMCID: PMCPMC3710581.

25. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011,481(7381):385-8. Epub 2011/11/22. doi: 10.1038/nature10642. PubMed PMID: 22101431, PubMed Central PMCID: PMCPMC3262117.

26. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer cell. 2005,8(4):311-21. Epub 2005/10/18. doi: 10.1016/j.ccr.2005.09.008. PubMed PMID: 16226706.

27. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nature reviews Cancer. 2011,11(5):325-37. Epub 2011/04/22. doi: 10.1038/nrc3038. PubMed PMID: 21508971.

28. Wu F, Li GZ, Liu HJ, Zhao Z, Chai RC, Liu YQ, et al. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. J Pathol. 2020,251(3):272-83. Epub 2020/05/18. doi: 10.1002/path.5468. PubMed PMID: 32418210.

29. Jiang T, Nam DH, Ram Z, Poon WS, Wang J, Boldbaatar D, et al. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer letters. 2021,499:60-72. Epub 2020/11/10. doi: 10.1016/j.canlet.2020.10.050. PubMed PMID: 33166616.
30. Wu F, Wang ZL, Wang KY, Li GZ, Chai RC, Liu YQ, et al. Classification of diffuse lower-grade glioma based on immunological profiling. Mol Oncol. 2020,14(9):2081-95. Epub 2020/05/12. doi: 10.1002/1878-0261.12707. PubMed PMID: 32392361, PubMed Central PMCID: PMCPMC7463381.

31. Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer letters. 2016,375(2):263-73. Epub 2016/03/12. doi: 10.1016/j.canlet.2016.01.024. PubMed PMID: 26966000.

32. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine. 2009,360(8):765-73. Epub 2009/02/21. doi: 10.1056/NEJMoa0808710. PubMed PMID: 19228619, PubMed Central PMCID: PMCPMC4530011.

33. Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, et al. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochir (Wien). 2016,158(10):1943-53. Epub 2016/08/17. doi: 10.1007/s00701-016-2928-8. PubMed PMID: 27526690.

34. Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England journal of medicine. 2015,372(26):2481-98. Epub 2015/06/11. doi: 10.1056/NEJMoa1402121. PubMed PMID: 26061751, PubMed Central PMCID: PMCPMC4530011.

35. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012,482(7385):400-4. Epub 2012/02/10. doi: 10.1038/nature10755. PubMed PMID: 22318521, PubMed Central PMCID: PMCPMC3874809.

36. Lu P, Wang Y, Liu X, Wang H, Zhang X, Wang K, et al. Malignant gliomas induce and exploit astrocytic mesenchymal-like transition by activating canonical Wnt/β-catenin signaling. Medical oncology (Northwood, London, England). 2016,33(7):66. Epub 2016/05/30. doi: 10.1007/s12032-016-0778-0. PubMed PMID: 27236327.

37. Walsh SH, Rosenquist R. Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis. Medical oncology (Northwood, London, England). 2005,22(4):327-41. Epub 2005/11/02. doi: 10.1385/mo:22:4:327. PubMed PMID: 16260850.

38. Ghraichy M, Galson JD, Kelly DF, Trück J. B-cell receptor repertoire sequencing in patients with primary immunodeficiency: a review. Immunology. 2018,153(2):145-60. Epub 2017/11/16. doi: 10.1111/imm.12865. PubMed PMID: 29140551, PubMed Central PMCID: PMCPMC5765381.

39. Lee YN, Frugoni F, Dobbs K, Tirosch I, Du L, Ververs FA, et al. Characterization of T and B cell repertoire diversity in patients with RAG deficiency. Sci Immunol. 2016,1(6). Epub 2017/08/08. doi: 10.1126/sciimmunol.aah6109. PubMed PMID: 28783691, PubMed Central PMCID: PMCPMC5586490.

40. Montfort A, Pearce O, Maniati E, Vincent BG, Bixby L, Böhm S, et al. A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017,23(1):250-62. Epub 2016/06/30. doi: 10.1158/1078-0432.Ccr-16-0081. PubMed PMID: 27354470, PubMed Central PMCID: PMCPMC5928522.
41. Wang JZ, Zhang YH, Guo XH, Zhang HY, Zhang Y. The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy. Int Immunopharmacol. 2016,36:73-85. Epub 2016/04/26. doi: 10.1016/j.intimp.2016.04.018. PubMed PMID: 27111515.

42. Sampson JH, Gunn MD, Fecsi PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nature reviews Cancer. 2020,20(1):12-25. Epub 2019/12/07. doi: 10.1038/s41568-019-0224-7. PubMed PMID: 31806885, PubMed Central PMCID: PMCPMC7327710.

43. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005,102(43):15545-50. Epub 2005/10/04. doi: 10.1073/pnas.0506580102. PubMed PMID: 16199517, PubMed Central PMCID: PMCPMC1239896.

44. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013,39(4):782-95. Epub 2013/10/22. doi: 10.1016/j.immuni.2013.10.003. PubMed PMID: 24138885.

45. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012,16(5):284-7. Epub 2012/03/30. doi: 10.1089/omi.2011.0118. PubMed PMID: 22455463, PubMed Central PMCID: PMCPMC3339379.

Figures

Figure 1

Expression analysis of SLC25A1 in different types of human cancers.
SLC25A1 is elevated in LGG. SLC25A1 showed prominently high expression in HCC samples than in normal samples via Wilcoxon rank sum test.
Figure 3

Association between SLC25A1 expression and clinicopathologic characteristics. Fig. 2 (A–J), elevated SLC25A1 was significantly correlated with (A) age, (B) gender, (C) race, (D) primary therapy outcome, (E) WHO grade, (F) OS event (G) PFI event, (H) DSS event, (I) 1p/19q codeletion, (J) IDH status.
Figure 4

Diagnostic value of SLC25A1 expression in LGG. ROC curve for SLC25A1 in normal tissue and tumor tissue.
Figure 5

Nomogram for predicting probability of patients with 1-, 3- and 5-year overall survival. For risk estimation, determine the status of each clinical factor and the expression value of SLC25A1, and draw a straight line on the point axis to see the number of points generated by a single factor. Repeat the above steps until the scores of all factors are determined. Sum these points and locate the summation points on the total point axis. Then draw the straight line down to the danger axis to get the survival probability related to 1, 3 and 5 years.
Figure 6

Survival outcomes based on Kaplan-Meier analysis. Kaplan-Meier survival analysis showed that increased SLC25A1 was prominently associated with better (A) overall survival, (B) disease-specific survival, (C) progression-free interval.

| Characteristics                      | Total(N) | HR(95% CI) Multivariate analysis | P value Multivariate analysis |
|--------------------------------------|----------|----------------------------------|------------------------------|
| WHO grade (G3 vs. G2)                | 466      | 2.001 (1.227-3.262)              | 0.005                        |
| 1p/19q codeletion (non-codel vs. codel) | 527      | 2.245 (1.238-4.068)              | 0.008                        |
| Primary therapy outcome (PR&CR vs. PD&SD) | 457      | 0.265 (0.140-0.501)              | <0.001                       |
| ERBB2 (High vs. Low)                 | 527      | 1.503 (0.964-2.344)              | 0.072                        |
| TP53 (High vs. Low)                  | 527      | 1.280 (0.814-2.014)              | 0.285                        |
| IDH status (Mut vs. WT)              | 524      | 0.447 (0.275-0.728)              | 0.001                        |
| Age (>40 vs. <=40)                   | 527      | 2.990 (1.873-4.774)              | <0.001                       |
| SLC25A1 (High vs. Low)               | 527      | 0.626 (0.401-0.984)              | 0.042                        |
| Histological type (Oligoastrocytoma&Oligodendroglioma vs. Astrocytoma) | 527      | 1.056 (0.661-1.695)              | 0.814                        |

Figure 7

Association between clinicopathologic characteristics and survival outcome of LGG patient through multivariate Cox regression analysis. SLC25A1 can independently predict overall survival.
Figure 8

SLC25A1 expression level has significant correlations with immune infiltration level in LGG.
Figure 9

SLC25A1 expression level is correlated with immune infiltration level in LGG. (A-B) positive correlation exists between the SLC25A1 expression level and infiltrating levels of CD8+ T cell, pDC. (C-R) negative correlation between the SLC25A1 expression level and infiltrating levels of Tcm, Thelper, TFH, Th1, Th2, aDC, B cells, Cytotoxic, Eosinophils, iDC, Macrophages, Mast, Neutrophils, CD56bright cells, CD56dim cells, NK cells, T cells.

Figure 10

Cumulative survival is related to B cell, CD8+ T cells, CD4+ T cells, Macrophage, Neutrophils and DCs in LGG. (The B cell, T cells, Macrophages, Neutrophils, and DCs are factors related to the cumulative survival rate of LGG over time).
Figure 11

The Functions of SLC25A1 and Genes Significantly Associated with SLC25A1 Alterations. The functions of SLC25A1 and genes significantly associated with SLC25A1 alterations were predicted by the analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) by DAVID tools (https://david.ncifcrf.gov/summary.jsp).
Figure 12

Enrichment plots by GSEA. (A) Neuroactive ligand receptor interaction, (B) cell adhesion molecules cams, (C) core matrisome, (D) CD8 tcr downstream pathway, (E) acetylcholine neurotransmitter release cycle, (F) barrestin pathway.